Seminars in Oncology
Volume 30, Issue 1 , Pages 57-71 , February 2003

Molecular and cellular biology of small cell lung cancer

References 

  1. Devereux TR, Taylor JA, Barrett JC. Molecular mechanisms of lung cancer. Chest. 1996;109(suppl):14S–19S
  2. Hibi K, Takahashi T, Yamakawa K, et al.  Three distinct regions involved in 3p deletion in human lung cancer. Oncogene. 1992;7:445–449
  3. Otterson G, Lin A, Kaye F. Genetic etiology of lung cancer. Oncology. 1992;6:97–112
  4. Kok K, Osinga J, Carritt B, et al.  Deletion of a DNA sequence at the chromosomal region 3p21 in all major types of lung cancer. Nature. 1987;330:578–581
  5. Naylor SL, Johnson BE, Minna JD, Sakaguchi AY. Loss of heterozygosity of chromosome 3p markers in small-cell lung cancer. Nature. 1987;329:451–454
  6. Dammann R, Li C, Yoon JH, et al.  Epigenetic inactivation of a RAS association domain family protein from the lung tumour suppressor locus 3p21.3. Nat Genet. 2000;25:315–319
  7. Burbee DG, Forgacs E, Zochbauer-Muller S, et al.  Epigenetic inactivation of RASSF1A in lung and breast cancers and malignant phenotype suppression. J Natl Cancer Inst. 2001;93:691–699
  8. Sozzi G, Veronese M, Negrini M, et al.  The FHIT gene at 3p14.2 is abnormal in lung cancer. Cell. 1996;85:17–26
  9. Ohta M, Inoue H, Cotticelli MG, et al.  The FHIT gene, spanning the chromosome 3p14.2 fragile site and renal carcinoma-associated t(3;8) breakpoint, is abnormal in digestive tract cancers. Cell. 1996;84:587–597
  10. Yunis JJ, Soreng AL. Constitutive fragile sites and cancer. Science. 1984;226:1199–1204
  11. Barnes LD, Garrison PN, Siprashvili Z, et al.  FHIT, a putative tumor suppressor in humans, is a dinucleoside 5',5'"-P1,P3-triphosphate hydrolase. Biochemistry. 1996;35:11529–11535
  12. Croce CM, Sozzi G, Huebner K. Role of FHIT in human cancer. J Clin Oncol. 1999;17:1618–1624
  13. Wistuba II, Gazdar AF, Minna JD. Molecular genetics of small cell lung carcinoma. Semin Oncol. 2001;28:3–13
  14. Mattei MG, Riviere M, Krust A, et al.  Chromosomal assignment of retinoic acid receptor (RAR) genes in the human, mouse, and rat genomes. Genomics. 1991;10:1061–1069
  15. Virmani AK, Rathi A, Zochbauer-Muller S, et al.  Promoter methylation and silencing of the retinoic acid receptor-beta gene in lung carcinomas. J Natl Cancer Inst. 2000;92:1303–1307
  16. Harley C, Kim N. Telomerase and cancer. In:  DeVita VJ,  Hellman S,  Rosenberg S editor. Important Advances in Oncology. vol 11:Philadelphia, PA: Lippincott-Raven; 1997;p. 1–11
  17. Carbone D. The biology of lung cancer. Semin Oncol. 1997;24:388–401
  18. Meyerson M. Role of telomerase in normal and cancer cells. J Clin Oncol. 2000;18:2626–2634
  19. Morin GB. The human telomere terminal transferase enzyme is a ribonucleoprotein that synthesizes TTAGGG repeats. Cell. 1989;59:521–529
  20. Hiyama K, Ishioka S, Shirotani Y, et al.  Alterations in telomeric repeat length in lung cancer are associated with loss of heterozygosity in p53 and rb. Oncogene. 1995;10:937–944
  21. Sarvesvaran J, Going JJ, Milroy R, et al.  Is small cell lung cancer the perfect target for anti-telomerase treatment?. Carcinogenesis. 1999;20:1649–1651
  22. Hiyama K, Hiyama E, Ishioka S, et al.  Telomerase activity in small-cell and non-small-cell lung cancers. J Natl Cancer Inst. 1995;87:895–902
  23. Salgia R, Skarin AT. Molecular abnormalities in lung cancer. J Clin Oncol. 1998;16:1207–1217
  24. Battey J, Moulding C, Taub R, et al.  The human c-myc oncogene: Structural consequences of translocation into the IgH locus in Burkitt lymphoma. Cell. 1983;34:779–787
  25. Taub R, Kirsch I, Morton C, et al.  Translocations of the c-myc gene into the immunoglobulin heavy chain locus in human Burkitt lymphoma and murine plasmacytoma cells. Proc Natl Acad Sci USA. 1982;79:7837–7841
  26. Dalla-Favera R, Bregni M, Erikson J, et al.  Human c-myc oncogene is located on the region of chromosome 8 that is translocated in Burkitt lymphoma. Proc Natl Acad Sci USA. 1982;79:7824–7827
  27. Blackwood E, Eisenman R. Max: A helix-loop-helix zipper protein that forms a sequence-specific DNA-binding complex with myc. Science. 1991;251:1211–1217
  28. Lemaitre J-M, Buckle R, Mechali M. c-myc in the control of cell proliferation and embryonic development. Adv Cancer Res. 1996;70:95–144
  29. Paget S. The distribution of secondary growths in cancer of the breast. Lancet. 1989;1:571–573
  30. Prins J, De Vries E, Mulder N. The myc family of oncogenes and their presence and importance in small-cell lung carcinoma and other tumour types. Anticancer Res. 1993;13:1373–1385
  31. Funa K, Steinholtz L, Nou E, et al.  Increased expression of N-myc in human small cell lung cancer biopsies predict lack of response to chemotherapy and poor prognosis. J Clin Pathol. 1986;88:216–220
  32. Noguchi M, Hirohasi S, Hara F. Heterogeneous amplification of myc family oncogenes in small cell lung carcinoma. Cancer. 1990;66:2053–2058
  33. Brennan J, O'Connor T, Makuch R, et al.  myc family DNA amplification in 107 tumors and tumor cell lines from patients with small cell lung cancer treated with different combination chemotherapy regimens. Cancer Res. 1991;51:1708–1712
  34. Johnson BE, Ihde DC, Makuch RW, et al.  myc family oncogene amplification in tumor cell lines established from small cell lung cancer patients and its relationship to clinical status and course. J Clin Invest. 1987;79:1629–1634
  35. Takahashi T, Obata Y, Sekido Y, et al.  Expression and amplification of myc gene family in small cell lung cancer and its relation to biological characteristics. Cancer Res. 1989;49:2683–2688
  36. Sirzen F, Zhivotovsky B, Nilsson A, et al.  Higher spontaneous apoptotic index in small cell compared with non-small cell lung carcinoma cell lines; lack of correlation with Bcl- 2/Bax. Lung Cancer. 1998;22:1–13
  37. Korsmeyer SJ. Regulators of cell death. Trends Genet. 1995;11:101–105
  38. Hale AJ, Smith CA, Sutherland LC, et al.  Apoptosis: Molecular regulation of cell death. Eur J Biochem. 1996;236:1–26
  39. Ruvolo PP, Deng X, May WS. Phosphorylation of Bcl2 and regulation of apoptosis. Leukemia. 2001;15:515–522
  40. Ohmori T, Podack ER, Nishio K, et al.  Apoptosis of lung cancer cells caused by some anti-cancer agents (MMC, CPT-11, ADM) is inhibited by bcl-2. Biochem Biophys Res Commun. 1993;192:30–36
  41. Kaiser U, Schilli M, Haag U, et al.  Expression of bcl-2–protein in small cell lung cancer. Lung Cancer. 1996;15:31–40
  42. Jiang SX, Sato Y, Kuwao S, et al.  Expression of bcl-2 oncogene protein is prevalent in small cell lung carcinomas. J Pathol. 1995;177:135–138
  43. Jiang SX, Kameya T, Sato Y, et al.  Bcl-2 protein expression in lung cancer and close correlation with neuroendocrine differentiation. Am J Pathol. 1996;148:837–846
  44. Maitra A, Amirkhan RH, Saboorian MH, et al.  Survival in small cell lung carcinoma is independent of Bcl-2 expression. Hum Pathol. 1999;30:712–717
  45. Brambilla E, Negoescu A, Gazzeri S, et al.  Apoptosis-related factors p53, Bcl2, and Bax in neuroendocrine lung tumors. Am J Pathol. 1996;149:1941–1952
  46. Banerjee D. Technology evaluation: G-3139. Curr Opin Mol Ther. 1999;1:404–408
  47. Zangemeister-Wittke U, Leech SH, Olie RA, et al.  A novel bispecific antisense oligonucleotide inhibiting both bcl-2 and bcl-xL expression efficiently induces apoptosis in tumor cells. Clin Cancer Res. 2000;6:2547–2555
  48. Kaelin WG. The p53 gene family. Oncogene. 1999;18:7701–7705
  49. Tokino T, Nakamura Y. The role of p53-target genes in human cancer. Crit Rev Oncol Hematol. 2000;33:1–6
  50. Mai M, Yokomizo A, Qian C, et al.  Activation of p73 silent allele in lung cancer. Cancer Res. 1998;58:2347–2349
  51. Nomoto S, Haruki N, Kondo M, et al.  Search for mutations and examination of allelic expression imbalance of the p73 gene at 1p36.33 in human lung cancers. Cancer Res. 1998;58:1380–1383
  52. Srivastava S, Zou ZQ, Pirollo K, et al.  Germ-line transmission of a mutated p53 gene in a cancer-prone family with Li-Fraumeni syndrome. Nature. 1990;348:747–749
  53. Malkin D, Li FP, Strong LC, et al.  Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. Science. 1990;250:1233–1238
  54. Yoshikawa H, Nagashima M, Khan MA, et al.  Mutational analysis of p73 and p53 in human cancer cell lines. Oncogene. 1999;18:3415–3421
  55. Sidransky D, Hollstein M. Clinical implications of the p53 gene. Annu Rev Med. 1996;47:285–301
  56. Kaelin WG. Recent insights into the functions of the retinoblastoma susceptibility gene product. Cancer Invest. 1997;15:243–254
  57. Knudson A. Hereditary cancer: Clues to mechanisms of carcinogenesis. Br J Cancer. 1989;59:661–666
  58. Flemington EK, Speck SH, Kaelin WG. E2F-1-mediated transactivation is inhibited by complex formation with the retinoblastoma susceptibility gene product. Proc Natl Acad Sci USA. 1993;90:6914–6918
  59. Helin K, Harlow E, Fattaey A. Inhibition of E2F-1 transactivation by direct binding of the retinoblastoma protein. Mol Cell Biol. 1993;13:6501–6508
  60. Yokota J, Akiyama T, Fung Y, et al.  Altered expression of the retinoblastoma (RB) gene in small cell lung cancer of the lung. Oncogene. 1988;3:471–475
  61. Harbour J, Lai S, Whang-Peng J, et al.  Abnormalities in structure and expression of the retinoblastoma gene in SCLC. Science. 1988;241:353–357
  62. Reeve J, Payne J, Bleehen N. Production of immunoreactive insulin-like growth factor-1 (IGF-1) and IGF-1 binding proteins by human lung tumors. Br J Cancer. 1990;61:727–731
  63. Minuto F, Del Monte P, Barreca A, et al.  Evidence for an increased somatomedin C/insulin-like growth factor-1 content in primary human lung tumors. Cancer Res. 1986;46:985–988
  64. Adams TE, Epa VC, Garrett TP, et al.  Structure and function of the type 1 insulin-like growth factor receptor. Cell Mol Life Sci. 2000;57:1050–1093
  65. Yu H, Spitz MR, Mistry J, et al.  Plasma levels of insulin-like growth factor-I and lung cancer risk: a case-control analysis. J Natl Cancer Inst. 1999;91:151–156
  66. Matthews W, Jordan CT, Wiegand GW, et al.  A receptor tyrosine kinase specific to hematopoietic stem and progenitor cell-enriched populations. Cell. 1991;65:1143–1152
  67. Ashman LK. The biology of stem cell factor and its receptor C-kit. Int J Biochem Cell Biol. 1999;31:1037–1051
  68. Linnekin D. Early signaling pathways activated by c-Kit in hematopoietic cells. Int J Biochem Cell Biol. 1999;31:1053–1074
  69. Hibi K, Takahashi T, Sekido Y, et al.  Coexpression of the stem cell factor and the c-kit genes in small-cell lung cancer. Oncogene. 1991;6:2291–2296
  70. Sekido Y, Obata Y, Ueda R, et al.  Preferential expression of c-kit protooncogene transcripts in small cell lung cancer. Cancer Res. 1991;51:2416–2419
  71. Rygaard K, Nakamura T, Spang-Thomsen M. Expression of the proto-oncogenes c-met and c-kit and their ligands, hepatocyte growth factor/scatter factor and stem cell factor, in SCLC cell lines and xenografts. Br J Cancer. 1993;67:37–46
  72. Sekido Y, Takahashi T, Ueda R, et al.  Recombinant human stem cell factor mediates chemotaxis of small-cell lung cancer cell lines aberrantly expressing the c-kit protooncogene. Cancer Res. 1993;53:1709–1714
  73. Plummer H, Catlett J, Leftwich J, et al.  c-myc expression correlates with suppression of c-kit protooncogene expression in small cell lung cancer cell lines. Cancer Res. 1993;53:4337–4342
  74. Krystal GW, Hines SJ, Organ CP. Autocrine growth of small cell lung cancer mediated by coexpression of c-kit and stem cell factor. Cancer Res. 1996;56:370–376
  75. Yamanishi Y, Maeda H, Hiyama K, et al.  Specific growth inhibition of small-cell lung cancer cells by adenovirus vector expressing antisense c-kit transcripts. Jpn J Cancer Res. 1996;87:534–542
  76. Wang WL, Healy ME, Sattler M, et al.  Growth inhibition and modulation of kinase pathways of small cell lung cancer cell lines by the novel tyrosine kinase inhibitor STI 571. Oncogene. 2000;19:3521–3528
  77. Krystal GW, Honsawek S, Litz J, et al.  The selective tyrosine kinase inhibitor STI571 inhibits small cell lung cancer growth. Clin Cancer Res. 2000;6:3319–3326
  78. Krystal GW, Honsawek S, Kiewlich D, et al.  Indolinone tyrosine kinase inhibitors block Kit activation and growth of small cell lung cancer cells. Cancer Res. 2001;61:3660–3668
  79. Kuenen BC, Rosen L, Smit EF, et al.  Dose-finding and pharmacokinetic study of cisplatin, gemcitabine, and SU5416 in patients with solid tumors. J Clin Oncol. 2002;20:1657–1667
  80. Iyer A, Kmiecik TE, Park M, et al.  Structure, tissue-specific expression, and transforming activity of the mouse met protooncogene. Cell Growth Differ. 1990;1:87–95
  81. Rong S, Bodescot M, Blair D, et al.  Tumorigenicity of the met proto-oncogene and the gene for hepatocyte growth factor. Mol Cell Biol. 1992;12:5152–5158
  82. Faletto DL, Tsarfaty I, Kmiecik TE, et al.  Evidence for non-covalent clusters of the c-met proto-oncogene product. Oncogene. 1992;7:1149–1157
  83. Stella MC, Comoglio PM. HGF: A multifunctional growth factor controlling cell scattering. Int J Biochem Cell Biol. 1999;31:1357–1362
  84. To CT, Tsao MS. The roles of hepatocyte growth factor/scatter factor and met receptor in human cancers (review). Oncol Rep. 1998;5:1013–1024
  85. Schmidt L, Junker K, Weirich G, et al.  Two North American families with hereditary papillary renal carcinoma and identical novel mutations in the MET proto-oncogene. Cancer Res. 1998;58:1719–1722
  86. Schmidt L, Junker K, Nakaigawa N, et al.  Novel mutations of the MET proto-oncogene in papillary renal carcinomas. Oncogene. 1999;18:2343–2350
  87. Maulik G, Kijima T, Ma PC, et al.  Modulation of the c-Met/hepatocyte growth factor pathway in small cell lung cancer. Clin Cancer Res. 2002;8:620–627
  88. Bardelli A, Longati P, Williams TA, et al.  A peptide representing the carboxyl-terminal tail of the met receptor inhibits kinase activity and invasive growth. J Biol Chem. 1999;274:29274–29281
  89. Atabey N, Gao Y, Yao ZJ, et al.  Potent blockade of hepatocyte growth factor-stimulated cell motility, matrix invasion and branching morphogenesis by antagonists of Grb2 Src homology 2 domain interactions. J Biol Chem. 2001;276:14308–14314
  90. Gual P, Giordano S, Williams TA, et al.  Sustained recruitment of phospholipase C-gamma to Gab1 is required for HGF-induced branching tubulogenesis. Oncogene. 2000;19:1509–1518
  91. Sporn M, Roberts A, Wakefield L, et al.  Some recent advances in the chemistry and biology of transforming growth factor-beta. J Cell Biol. 1987;105:1039–1045
  92. Norgaard P, Spang-Thomsen M, Poulsen HS. Expression and autoregulation of transforming growth factor beta receptor mRNA in small-cell lung cancer cell lines. Br J Cancer. 1996;73:1037–1043
  93. Heldin CH, Miyazono K, ten Dijke P. TGF-beta signalling from cell membrane to nucleus through SMAD proteins. Nature. 1997;390:465–471
  94. Uchida K, Nagatake M, Osada H, et al.  Somatic in vivo alterations of the JV18-1 gene at 18q21 in human lung cancers. Cancer Res. 1996;56:5583–5585
  95. Nagatake M, Takagi Y, Osada H, et al.  Somatic in vivo alterations of the DPC4 gene at 18q21 in human lung cancers. Cancer Res. 1996;56:2718–2720
  96. Riggins GJ, Kinzler KW, Vogelstein B, et al.  Frequency of Smad gene mutations in human cancers. Cancer Res. 1997;57:2578–2580
  97. Gerwin BI, Spillare E, Forrester K, et al.  Mutant p53 can induce tumorigenic conversion of human bronchial epithelial cells and reduce their responsiveness to a negative growth factor, transforming growth factor beta 1. Proc Natl Acad Sci USA. 1992;89:2759–2763
  98. Gutkind JS. Cell growth control by G protein-coupled receptors: From signal transduction to signal integration. Oncogene. 1998;17:1331–1342
  99. Moody T, Pert CB, Gazdar A, et al.  High levels of intracellular bombesin characterize human small cell lung carcinoma. Science. 1981;214:1246–1248
  100. Spindel E, Chin W, Price J, et al.  Cloning and characterization of cDNAs encoding human gastrin-releasing peptide. Proc Natl Acad Sci USA. 1984;81:5699–5703
  101. Sausville E, Lebacq-Verheyden A, Spindel E, et al.  Expression of the gastrin releasing peptide gene in human small cell lung cancer. J Biol Chem. 1986;261:2451–2459
  102. Cuttitta F, Carney DN, Mulshine J, et al.  Bombesin-like peptides can function as autocrine growth factors in human small-cell lung cancer. Nature. 1985;316:823–826
  103. Miyake Y, Kodama T, Yamaguchi K. Pro-gastrin-releasing peptide(31-98) is a specific tumor marker in patients with small cell lung carcinoma. Cancer Res. 1994;54:2136–2140
  104. Chaudhry A, Carrasquillo JA, Avis IL, et al.  Phase I and imaging trial of a monoclonal antibody directed against gastrin-releasing peptide in patients with lung cancer. Clin Cancer Res. 1999;5:3385–3393
  105. Kojika S, Griffin JD. Notch receptors and hematopoiesis. Exp Hematol. 2001;29:1041–1052
  106. Dang TP, Gazdar AF, Virmani AK, et al.  Chromosome 19 translocation, overexpression of Notch3, and human lung cancer. J Natl Cancer Inst. 2000;92:1355–1357
  107. Sriuranpong V, Borges MW, Ravi RK, et al.  Notch signaling induces cell cycle arrest in small cell lung cancer cells. Cancer Res. 2001;61:3200–3205
  108. Borges M, Linnoila RI, van de Velde HJ, et al.  An achaete-scute homologue essential for neuroendocrine differentiation in the lung. Nature. 1997;386:852–855
  109. Linnoila RI, Zhao B, DeMayo JL, et al.  Constitutive achaete-scute homologue-1 promotes airway dysplasia and lung neuroendocrine tumors in transgenic mice. Cancer Res. 2000;60:4005–4009
  110. Souhami R, Beverley P, Bobrow L. Proceedings of the First International Workshop on Small Cell Lung Cancer. Lancet. 1987;2:325–326
  111. Souhami R, Beverley P, Bobrow L, et al.  Antigens of lung cancer: Results of the Second International Workshop on Lung Cancer Antigens. J Natl Cancer Inst. 1991;83:609–612
  112. Stahel R, Gilks W, Schenker T. Antigens of lung cancer: Results of the Third International Workshop on Lung Tumor and Differentiation Antigens. J Natl Cancer Inst. 1994;86:669–672
  113. Moolenaar C, Muller E, Schol D. Expression of the neural cell adhesion molecule-related sialoglycoprotien in small cell lung cancer and neuroblastoma cell lines H69 and CHP-212. Cancer Res. 1990;50:1102–1106
  114. Kibbelaar R, Moolenaar C, Michalides R, et al.  Expression of the embryonal neural cell adhesion molecule N-CAM in lung carcinoma. Diagnostic usefulness of monoclonal antibody 735 for the distinction betweeen small cell lung cancer and non-small cell lung cancer. J Pathol. 1989;159:23–28
  115. Lynch TJ, Lambert JM, Coral F, et al.  Immunotoxin therapy of small-cell lung cancer: A phase I study of N901- blocked ricin. J Clin Oncol. 1997;15:723–734
  116. Moore SM, Rintoul RC, Walker TR, et al.  The presence of a constitutively active phosphoinositide 3-kinase in small cell lung cancer cells mediates anchorage-independent proliferation via a protein kinase B and p70s6k-dependent pathway. Cancer Res. 1998;58:5239–5247
  117. Carpenter CL, Cantley LC. Phosphoinositide kinases. Curr Opin Cell Biol. 1996;8:153–158
  118. Rameh LE, Cantley LC. The role of phosphoinositide 3-kinase lipid products in cell function. J Biol Chem. 1999;274:8347–8350
  119. Vanhaesebroeck B, Waterfield MD. Signaling by distinct classes of phosphoinositide 3-kinases. Exp Cell Res. 1999;253:239–254
  120. Berrie CP. Phosphoinositide 3-kinase inhibition in cancer treatment. Expert Opin Invest Drugs. 2001;10:1085–1098
  121. Stein RC. Prospects for phosphoinositide 3-kinase inhibition as a cancer treatment. Endocr Relat Cancer. 2001;8:237–248
  122. Belham C, Wu S, Avruch J. Intracellular signalling: PDK1—A kinase at the hub of things. Curr Biol. 1999;9:R93–R96
  123. Datta SR, Brunet A, Greenberg ME. Cellular survival: A play in three Akts. Genes Dev. 1999;13:2905–2927
  124. Vanhaesebroeck B, Alessi DR. The PI3K-PDK1 connection: More than just a road to PKB. Biochem J. 2000;346(Pt 3):561–576
  125. Brazil DP, Hemmings BA. Ten years of protein kinase B signalling: A hard Akt to follow. Trends Biochem Sci. 2001;26:657–664
  126. Kops GJ, Burgering BM. Forkhead transcription factors: New insights into protein kinase B (c-akt) signaling. J Mol Med. 1999;77:656–665
  127. Seufferlein T, Rozengurt E. Rapamycin inhibits constitutive p70s6k phosphorylation, cell proliferation, and colony formation in small cell lung cancer cells. Cancer Res. 1996;56:3895–3897
  128. Hidalgo M, Rowinsky E, Erlichman C, et al.  CCI-779, a rapamycin analog and multifaceted inhibitor of signal transduction: A phase I study. Proc Am Soc Clin Oncol. 2000;19:182a; (abstr 726)
  129. Cantley LC, Neel BG. New insights into tumor suppression: PTEN suppresses tumor formation by restraining the phosphoinositide 3-kinase/AKT pathway. Proc Natl Acad Sci USA. 1999;96:4240–4245
  130. Kim SK, Su LK, Oh Y, et al.  Alterations of PTEN/MMAC1, a candidate tumor suppressor gene, and its homologue, PTH2, in small cell lung cancer cell lines. Oncogene. 1998;16:89–93
  131. Kohno T, Takahashi M, Manda R, et al.  Inactivation of the PTEN/MMAC1/TEP1 gene in human lung cancers. Genes Chromosomes Cancer. 1998;22:152–156
  132. Forgacs E, Biesterveld EJ, Sekido Y, et al.  Mutation analysis of the PTEN/MMAC1 gene in lung cancer. Oncogene. 1998;17:1557–1565
  133. Hong TM, Yang PC, Peck K, et al.  Profiling the downstream genes of tumor suppressor PTEN in lung cancer cells by complementary DNA microarray. Am J Respir Cell Mol Biol. 2000;23:355–363
  134. Basu A. The potential of protein kinase C as a target for anticancer treatment. Pharmacol Ther. 1993;59:257–280
  135. Blobe GC, Obeid LM, Hannun YA. Regulation of protein kinase C and role in cancer biology. Cancer Metastasis Rev. 1994;13:411–431
  136. Goekjian PG, Jirousek MR. Protein kinase C inhibitors as novel anticancer drugs. Expert Opin Invest Drugs. 2001;10:2117–2140
  137. Lo SH, Chen LB. Focal adhesion as a signal transduction organelle. Cancer Metastasis Rev. 1994;13:9–24
  138. Hynes RO. Integrins: Versatility, modulation, and signaling in cell adhesion. Cell. 1992;69:11–25
  139. Guo N, Templeton NS, Al-Barazi H, et al.  Thrombospondin-1 promotes alpha3beta1 integrin-mediated adhesion and neurite-like outgrowth and inhibits proliferation of small cell lung carcinoma cells. Cancer Res. 2000;60:457–466
  140. Sethi T, Rintoul RC, Moore SM, et al.  Extracellular matrix proteins protect small cell lung cancer cells against apoptosis: A mechanism for small cell lung cancer growth and drug resistance in vivo. Nat Med. 1999;5:662–668
  141. Ambros VR, Chen LB, Buchanan JM. Surface ruffles as markers for studies of cell transformation by Rous sarcoma virus. Proc Natl Acad Sci USA. 1975;72:3144–3148
  142. Bernal SD, Baylin SB, Shaper JH, et al.  Cytoskeleton-associated proteins of human lung cancer cells. Cancer Res. 1983;43:1798–1808
  143. Salgia R, Li JL, Lo SH, et al.  Molecular cloning of human paxillin, a focal adhesion protein phosphorylated by P210BCR/ABL. J Biol Chem. 1995;270:5039–5047
  144. Salgia R, Li JL, Ewaniuk DS, et al.  Expression of the focal adhesion protein paxillin in lung cancer and its relation to cell motility. Oncogene. 1999;18:67–77
  145. Bockholt SM, Burridge K. Cell spreading on extracellular matrix proteins induces tyrosine phosphorylation of tensin. J Biol Chem. 1993;268:14565–14567
  146. Salgia R, Avraham S, Pisick E, et al.  The related adhesion focal tyrosine kinase forms a complex with paxillin in hematopoietic cells. J Biol Chem. 1996;271:31222–31226
  147. Salgia R, Pisick E, Sattler M, et al.  p130CAS forms a signaling complex with the adapter protein CRKL in hematopoietic cells transformed by the BCR/ABL oncogene. J Biol Chem. 1996;271:25198–25203
  148. Schaller MD, Otey CA, Hildebrand JD, et al.  Focal adhesion kinase and paxillin bind to peptides mimicking beta integrin cytoplasmic domains. J Cell Biol. 1995;130:1181–1187
  149. Adler V, Yin Z, Tew KD, et al.  Role of redox potential and reactive oxygen species in stress signaling. Oncogene. 1999;18:6104–6111
  150. Kamata H, Hirata H. Redox regulation of cellular signalling. Cell Signal. 1999;11:1–14
  151. Rahman I, MacNee W. Role of oxidants/antioxidants in smoking-induced lung diseases. Free Radic Biol Med. 1996;21:669–681
  152. Guan KL, Dixon JE. Evidence for protein-tyrosine-phosphatase catalysis proceeding via a cysteine-phosphate intermediate. J Biol Chem. 1991;266:17026–17030
  153. Barrett WC, DeGnore JP, Keng YF, et al.  Roles of superoxide radical anion in signal transduction mediated by reversible regulation of protein-tyrosine phosphatase 1B. J Biol Chem. 1999;274:34543–34546
  154. Lander HM, Hajjar DP, Hempstead BL, et al.  A molecular redox switch on p21ras. Structural basis for the nitric oxide-p21ras interaction. J Biol Chem. 1997;272:4323–4326
  155. Suh Y-A, Arnold RS, Lassegue B, et al.  Cell transformation by the superoxide-generating oxidase Mox1. Nature. 1999;401:79–82
  156. Huang P, Feng L, Oldham EA, et al.  Superoxide dismutase as a target for the selective killing of cancer cells. Nature. 2000;407:390–395

☆ Address reprint requests to Ravi Salgia, MD, PhD, Assistant Professor of Medicine, Harvard Medical School, Dana-Farber Cancer Institute, Dana 730B, 44 Binney St, Boston, MA 02115.

PII: S0093-7754(03)70043-8

doi: 10.1053/sonc.2003.50019

Seminars in Oncology
Volume 30, Issue 1 , Pages 57-71 , February 2003

Article Tools

* Image Usage & Resolution